Spelling suggestions: "subject:"[een] BETA AMYLOID"" "subject:"[enn] BETA AMYLOID""
61 |
Mise au point d’un nouveau modèle d’organoïde cérébral humain pour l’étude des mécanismes d’interaction de la protéine prion et de l’amyloïde β / Set Up of a New Human Cerebral Organoid Model to Study the Interaction Mechanisms of Prion and β Amyloid ProteinsPavoni, Serena 13 December 2017 (has links)
Les mécanismes de type prion sont désormais reconnus comme sous-tendant la plupart des maladies neurodégénératives humaines, avec en premier lieu la maladie d’Alzheimer (MA) au niveau de ses 2 marqueurs spécifiques, l’amyloïde β (Aβ à l’origine de l’hypothèse étiopathogénique de la cascade amyloïde) et la protéine Tau phosphorylée. Par ailleurs la protéine du prion (PrPC) est décrite comme interagissant à de multiples niveaux avec le métabolisme de l’Aβ sans que les mécanismes physiopathologiques sous-jacents n’aient pu être expliqués. Pour sortir de l’impasse actuelle concernant le développement d’approches thérapeutiques efficaces pour la MA, l’industrie pharmaceutique a besoin de modèles expérimentaux innovants. En effet, à ce jour aucun modèle in vivo, en dépit des progrès réalisés avec les souris transgéniques, n’arrive à refléter la complexité cérébrale humaine ni à mimer une MA clinique. Les cultures in vitro en 2D sont quant à elles très éloignées des situations conduisant à l’accumulation d’agrégats protéiques pathologiques. Le but de notre thèse a été d’utiliser dans le domaine des neurosciences les nouvelles perspectives de recherche ouvertes par les technologies des cellules souches pluripotentes induites (cellules iPS) en développant un modèle de différentiation en 3D pour obtenir des organoïdes cérébraux humains (OC) (mini cerveaux). Leur capacité d’auto-organisation en 3D de tissu neuroectodermique nous a permis de recréer un système complexe mimant différentes structures cérébrales humaines dans lesquelles nous avons pu caractériser les marqueurs attendus. L’étude de l’expression des protéines d’intérêt APP et PrPC pendant la différentiation neurale a permis de caractériser la modulation des niveaux des deux protéines en fonction du temps de culture. Afin d’orienter le modèle vers des mécanismes d’accumulation protéique de type MA, nous avons testé différents inducteurs chimiques dont l’Aftin-5 qui est capable de moduler les voies post-traductionnelles de l’APP. Plusieurs stratégies de traitement ont été adoptées pour induire le clivage de l’APP et la génération d’Aβ. La production des fragments solubles Aβ38, Aβ40, Aβ42 a été mise en évidence par ELISA. Les niveaux générés sont reproductibles et l’augmentation du ratio Aβ42/Aβ40 est cohérente avec les données extrapolées des modèles murins et humains, ce qui a permis de valider notre modèle. Les niveaux d’expression génique et protéique de PrPC et de APP suite au traitement ont été analysés afin de mieux déterminer le rôle de l’interaction entre ces deux facteurs. L’objectif à long terme consiste à améliorer ce modèle, dont les limites actuelles sont notamment l’absence de vascularisation et le niveau de maturation du tissu neural. Le défi majeur dans le cadre de la culture des OC consiste donc à favoriser l’intégration du système vasculaire, et par ailleurs à accélérer le vieillissement in vitro pour l’étude de maladies neurodégénératives. La perspective de pouvoir automatiser le système de culture des OC permet d’envisager l’utilisation de ce modèle à plus grande échelle dans le cadre de test de cytotoxicité et/ou de criblage pharmacologique à haut débit pour identifier de nouvelles molécules thérapeutiques pour la MA. / Prion-like mechanisms are known to underlie most of human neurodegenerative diseases including Alzheimer’s disease (AD), which is characterized by two important pathological markers, β amyloid (or Aβ at the origin of the etiopathogenic amyloid cascade hypothesis) and phosphorylated tau protein. Furthermore, the prion protein (PrPC) interacts at multiple levels with the metabolism of Aβ, by mechanisms which are not well understood. To overcome the current limits in the development of efficient strategies to treat AD, the pharmaceutical industry requires innovative experimental models. However, even if a lot of progress has been achieved by using transgenic mouse models, to date no in vivo model can reflect the complexity of human brain or reproduce a clinical context. 2D in vitro cell culture models are unable to allow the aggregation and accumulation of pathological proteins as observed in vivo. The aim of this study consists in taking advantage of the research prospects offered by induced pluripotent stem cell (iPSCs) in the field of neurosciences. iPSCs can be used to generate 3D models of differentiation also called human cerebral organoids or mini-brains (MBs). Their ability to self-organise in 3D neuroectodermic tissue leds to a complex system that mimics different human cerebral structures in which we were able to characterize the expected markers. The study of the two proteins of interest (APP and PrPC) during neural differentiation has allowed us to follow the modulation of protein expression level occurring during the in vitro development of the human MBs. In order to use this model to reproduce the protein accumulation mechanisms seen in AD, we have tested chemical inductors such as Aftin-5 in order to modulate the APP post-transcriptional pathway towards a pathological outcome. Many strategies of treatment are adopted to lead APP cleavage and Aβ generation. The production of soluble fragments Aβ38, Aβ40, Aβ42 in the supernatant of organoids has been showed using ELISA technique. The levels generated are reproducible and the increase of Aβ42/Aβ40 ratio is consistent with extrapolated data from mouse and human models thus validating our model. Analysis at the gene and protein level has been assessed in order to understand the interaction between PrPC and APP after treatment. The long-term goal consists in improving this model which is notably hampered by the absence of vascularization and the low level of maturation of the neural tissue. The main challenge in MB culture thus consists in the integration of the vascular system, and also in increasing the speed of ageing process in vitro for the study of neurodegenerative diseases. In the long term, the prospect of automating the culture of MBs would allow the use of the system for cytotoxicity testing and/or high throughput screening for the discovery of new drugs for AD.
|
62 |
"A influência do lítio no risco para a doença de Alzheimer" / The influence of lithium on the risk of Alzheimer's diseaseNunes, Paula Villela 10 March 2006 (has links)
O lítio é freqüentemente utilizado no tratamento do Transtorno Bipolar, doença associada a um risco aumentado para demência. Evidências experimentais sugerem efeitos neuroproterores do lítio. O lítio inibe a amiloidogênese e a fosforilação da proteína tau tanto in vitro como in vivo. Estes são processos importantes na patogênese da doença de Alzheimer. O objetivo este estudo foi a investigação do efeito do lítio na prevalência de Transtorno Cognitivo Leve e doença de Alzheimer em 114 bipolares idosos eutímicos. Todos os sujeitos completaram uma avaliação catamnéstica, psicopatológica e cognitiva que incluía o mini-exame do estado mental (Mini-mental), o teste cognitivo de Cambridge (CAMCOG) e o questionário do informante sobre o declínio cognitivo do idoso (IQCODE). Foi feita uma comparação da prevalência de Transtorno Cognitivo Leve e doença de Alzheimer entre pacientes em uso de lítio e pacientes em uso de outros estabilizadores de humor. Os sujeitos que entraram na pesquisa tinham em média 68,2 ± 5,0 anos e preenchiam os critérios da Décima Revisão da Classificação Internacional de Doenças e Problemas de Saúde Relacionados (CID-10) para o transtorno bipolar. Durante a avaliação os bipolares estavam eutímicos. Eutimia foi definida como uma pontuação máxima de 7 pontos na escala de Hamilton de 21 pontos para Depressão e 4 na escala de Young para mania. 66 pacientes em uso contínuo do lítio por 6 anos em média foram comparados com 48 pacientes em tratamento com outros estabilizadores de humor. O diagnóstico de Transtorno Cognitivo Leve foi feito de acordo com os critérios de Petersen(1999) e de doença de Alzheimer de acordo com o critério do National Institute for Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association" (NINCDS/ADRDA). A prevalência de demência nesta amostra (19,4%) foi mais elevada do que o esperado para uma população comparável (7,1%). A prevalência de doença de Alzheimer entre aqueles com lítio foi 4,5% quando comparada com 33,3% entre aqueles sem lítio. Controlando idade e outras variáveis relacionadas ao curso da doença, o efeito do lítio na prevalência de doença de Alzheimer permaneceu significativo (OR = 0,079; p < 0,001). Nenhuma associação foi encontrada com Transtorno Cognitivo Leve. A alta da prevalência de doença de Alzheimer neste estudo está de acordo com as evidências de risco aumentado para demência em pacientes bipolares. Nesta amostra o tratamento com lítio reduziu a prevalência de Alzheimer aos níveis da população idosa em geral. Estes achados estão de acordo com os efeitos neuroprotetores do lítio em eventos cruciais para a patologia da doença de Alzheimer. Estudos prospectivos são necessários para avaliar se o lítio também pode ser efetivo na prevenção de doença de Alzheimer em outras populações. / Lithium is widely used in the treatment of bipolar disorder, a condition associated with an increased risk for dementia. Experimental evidence suggests that lithium has a neuroprotective effect. Both in vitro and in vivo, lithium inhibits amyloidogenesis and phosphorilation of tau protein, which are two crucial processes in the pathogenesis of Alzheimers disease. The objective of this study was to investigate the effect of lithium on the prevalence of Mild Cognitive Impairment and Alzheimers disease in 114 elderly euthymic bipolar patients. Subjects completed a thorough catamnestic, psychopathological and cognitive tests evaluation including the Mini-mental state evaluation, Cambridge cognitive test (CAMCOG) and the informant questionnaire on cognitive decline in the elderly (IQCODE). The prevalence of Mild Cognitive Impairment and Alzheimers disease between patients on lithium therapy and patients on treatment with other mood-stabilizing drugs was compared. Patients were 68.2 ± 5.0 years old and fulfilled of the International Classification of Diseases - 10th Revision (ICD-10) diagnosis for bipolar disorder. At the time of the evaluation patients were euthymic, as defined by a maximum score of 7 in the 21-item Hamilton Rating Scale for Depression, and 4 in the Young Mania Rating Scale. Sixty-six patients were continuously being treated with lithium for six years, on average, and 48 patients were receiving other mood-stabilizing drugs. Diagnosis of Mild Cognitive Impairment was made according to Petersen (1999) and of Alzheimers disease was made according to the National Institute for Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association (NINCDS/ADRDA) criteria. The overall prevalence of dementia in our sample (19.4%) was higher than the prevalence expected in the age-comparable general population (7.1%). The prevalence of Alzheimers disease among lithium users was 4.5% as compared to 33.3% among non-users. After controlling for age and other variables related to the clinical course of the bipolar disorder, the effect of lithium on Alzheimers disease prevalence remained significant (OR = 0.079; p < 0.001). No association was found with Mild Cognitive Impairment. The higher prevalence of Alzheimers disease in our study supports the reports of increased risk for dementia in bipolar patients. In our sample, lithium treatment reduced the prevalence of Alzheimers disease to the levels of the general elderly population. This finding is in line with the neuroprotective effects of lithium on crucial events for the pathology of Alzheimers disease. Further prospective studies are needed to clarify whether lithium may also be effective in the prevention of Alzheimers disease in the general population.
|
63 |
"A influência do lítio no risco para a doença de Alzheimer" / The influence of lithium on the risk of Alzheimer's diseasePaula Villela Nunes 10 March 2006 (has links)
O lítio é freqüentemente utilizado no tratamento do Transtorno Bipolar, doença associada a um risco aumentado para demência. Evidências experimentais sugerem efeitos neuroproterores do lítio. O lítio inibe a amiloidogênese e a fosforilação da proteína tau tanto in vitro como in vivo. Estes são processos importantes na patogênese da doença de Alzheimer. O objetivo este estudo foi a investigação do efeito do lítio na prevalência de Transtorno Cognitivo Leve e doença de Alzheimer em 114 bipolares idosos eutímicos. Todos os sujeitos completaram uma avaliação catamnéstica, psicopatológica e cognitiva que incluía o mini-exame do estado mental (Mini-mental), o teste cognitivo de Cambridge (CAMCOG) e o questionário do informante sobre o declínio cognitivo do idoso (IQCODE). Foi feita uma comparação da prevalência de Transtorno Cognitivo Leve e doença de Alzheimer entre pacientes em uso de lítio e pacientes em uso de outros estabilizadores de humor. Os sujeitos que entraram na pesquisa tinham em média 68,2 ± 5,0 anos e preenchiam os critérios da Décima Revisão da Classificação Internacional de Doenças e Problemas de Saúde Relacionados (CID-10) para o transtorno bipolar. Durante a avaliação os bipolares estavam eutímicos. Eutimia foi definida como uma pontuação máxima de 7 pontos na escala de Hamilton de 21 pontos para Depressão e 4 na escala de Young para mania. 66 pacientes em uso contínuo do lítio por 6 anos em média foram comparados com 48 pacientes em tratamento com outros estabilizadores de humor. O diagnóstico de Transtorno Cognitivo Leve foi feito de acordo com os critérios de Petersen(1999) e de doença de Alzheimer de acordo com o critério do National Institute for Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association (NINCDS/ADRDA). A prevalência de demência nesta amostra (19,4%) foi mais elevada do que o esperado para uma população comparável (7,1%). A prevalência de doença de Alzheimer entre aqueles com lítio foi 4,5% quando comparada com 33,3% entre aqueles sem lítio. Controlando idade e outras variáveis relacionadas ao curso da doença, o efeito do lítio na prevalência de doença de Alzheimer permaneceu significativo (OR = 0,079; p < 0,001). Nenhuma associação foi encontrada com Transtorno Cognitivo Leve. A alta da prevalência de doença de Alzheimer neste estudo está de acordo com as evidências de risco aumentado para demência em pacientes bipolares. Nesta amostra o tratamento com lítio reduziu a prevalência de Alzheimer aos níveis da população idosa em geral. Estes achados estão de acordo com os efeitos neuroprotetores do lítio em eventos cruciais para a patologia da doença de Alzheimer. Estudos prospectivos são necessários para avaliar se o lítio também pode ser efetivo na prevenção de doença de Alzheimer em outras populações. / Lithium is widely used in the treatment of bipolar disorder, a condition associated with an increased risk for dementia. Experimental evidence suggests that lithium has a neuroprotective effect. Both in vitro and in vivo, lithium inhibits amyloidogenesis and phosphorilation of tau protein, which are two crucial processes in the pathogenesis of Alzheimers disease. The objective of this study was to investigate the effect of lithium on the prevalence of Mild Cognitive Impairment and Alzheimers disease in 114 elderly euthymic bipolar patients. Subjects completed a thorough catamnestic, psychopathological and cognitive tests evaluation including the Mini-mental state evaluation, Cambridge cognitive test (CAMCOG) and the informant questionnaire on cognitive decline in the elderly (IQCODE). The prevalence of Mild Cognitive Impairment and Alzheimers disease between patients on lithium therapy and patients on treatment with other mood-stabilizing drugs was compared. Patients were 68.2 ± 5.0 years old and fulfilled of the International Classification of Diseases - 10th Revision (ICD-10) diagnosis for bipolar disorder. At the time of the evaluation patients were euthymic, as defined by a maximum score of 7 in the 21-item Hamilton Rating Scale for Depression, and 4 in the Young Mania Rating Scale. Sixty-six patients were continuously being treated with lithium for six years, on average, and 48 patients were receiving other mood-stabilizing drugs. Diagnosis of Mild Cognitive Impairment was made according to Petersen (1999) and of Alzheimers disease was made according to the National Institute for Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association (NINCDS/ADRDA) criteria. The overall prevalence of dementia in our sample (19.4%) was higher than the prevalence expected in the age-comparable general population (7.1%). The prevalence of Alzheimers disease among lithium users was 4.5% as compared to 33.3% among non-users. After controlling for age and other variables related to the clinical course of the bipolar disorder, the effect of lithium on Alzheimers disease prevalence remained significant (OR = 0.079; p < 0.001). No association was found with Mild Cognitive Impairment. The higher prevalence of Alzheimers disease in our study supports the reports of increased risk for dementia in bipolar patients. In our sample, lithium treatment reduced the prevalence of Alzheimers disease to the levels of the general elderly population. This finding is in line with the neuroprotective effects of lithium on crucial events for the pathology of Alzheimers disease. Further prospective studies are needed to clarify whether lithium may also be effective in the prevention of Alzheimers disease in the general population.
|
64 |
Multifunctional magnetic and fluorescent nanoparticles for beta-amyloid targeting in neurodegenerative disease diagnosis / Développement de nanoparticules magnétiques et fluorescentes pour le ciblage de béta-amyloide dans le diagnostic des maladies neurodégénérativesMpambani, Francis 28 May 2013 (has links)
Avec 35 millions de personnes atteintes dans le monde, la maladie d'Alzheimer (MA) est la maladie neurodégénérative la plus répandue. L'une des caractéristiques pathologiques de cette maladie est l'apparition de plaques amyloïdes, composées d'agrégats de peptide beta-amyloïde. Aujourd'hui, le diagnostic repose essentiellement sur des tests neuropsychologiques et sur la mise en évidence de changements dans la structure du cerveau tels que l'atrophie corticale (diminution du volume du cerveau). Cependant les symptômes de cette maladie n'apparaissent qu'à un stade très développé. Ainsi la détection in vivo des dépôts de peptide beta-amyloïde avant le développement de la maladie pourrait conduire à un diagnostic plus précoce et plus probant. Elle pourrait également faciliter le suivi et l'évaluation des effets des interventions thérapeutiques au cours du traitement. Dans ce travail, nous avons développé une méthode de diagnostic précoce innovante, capable de cibler et de détecter les plaques Abeta à la fois par l'imagerie par résonance magnétique et par l'imagerie de fluorescence. Nous avons développé un nouveau type d'agents de contraste intelligents pour l'imagerie multimodale, basé sur des nanoparticules magnétiques sur lesquelles sont greffés les polythiophènes luminescents (LCPs). Les LCPs à la surface des nanoparticules magnétiques se lient aux plaques Abeta de manière sélective et spécifique. Lors de cette liaison, la liberté conformationnelle des polythiophènes se trouve limitée, ce qui conduit à des spectres d'émission spécifiques dépendant de la conformation, et rend pertinent l'usage de l'imagerie par résonance magnétique et de fluorescence des plaques Abeta / Alzheimer's disease is the most common neurodegenerative disorder, affecting around 35 million people worldwide. One of the characteristic pathological hallmarks of AD is amyloid plaques; consist of beta-amyloid peptide aggregates. Today’s diagnosis depends essentially on neuropsychological tests and in highlighting change in brain structure such as cortical atrophy. A major issue is that symptoms appear only at a developed stage of the disease. Then in vivo detection of beta-amyloid deposits at an early stage could lead to earlier and more conclusive diagnosis of AD and help monitoring the effect of therapeutic interventions. In this work, we develop an innovative and early diagnosis method, able to target and detect beta-amyloid deposits aggregates both by magnetic resonance and fluorescence imaging. Thus we develop a new kind of smart contrast agent for multimodal imaging, based on magnetic nanoparticles on which are grafted luminescent conjugated polythiophenes (LCPs). LCPs on the surface of the magnetic nanoparticles bound to beta-amyloid aggregates selectively and specifically. Upon biding to beta-amyloid aggregates the conformational freedom of the backbone is restricted, leading to specific conformation-dependent emission spectra from the LCPs, opening the way for magnetic resonance and fluorescence imaging of the beta-amyloid plaques
|
65 |
Impact de la charge amyloïde, des lésions de la substance blanche et des changements de la matière grise sur la cognition dans le vieillissement normalSévigny Dupont, Pénélope 08 1900 (has links)
La prévalence de changements cérébraux pathologiques dans la population âgée est très élevée, même chez des individus en bonne santé et pleinement autonomes. L’accumulation anormale de la protéine bêta-amyloïde (A), un biomarqueur-clé de la maladie d’Alzheimer (MA), et les hypersignaux de la substance blanche (HSB), qui sont des lésions des petits vaisseaux cérébraux de la substance blanche, sont parmi les pathologies cérébrales liées à l’âge les plus répandues. Un ensemble de preuves scientifiques s’appuyant sur des données neuropathologiques, neuropsychologiques et d’imagerie cérébrale suggère que les personnes âgées cognitivement normales ayant une charge lésionnelle cérébrale importante présentent un déclin cognitif accentué. Ainsi, les changements neuropathologiques chez les aînés en bonne santé sont particulièrement intéressants, car ils constituent des cibles thérapeutiques prometteuses et pourraient contribuer au dépistage précoce de la MA. Cette thèse avait pour but d’examiner les associations entre la charge A, les HSB et l’épaisseur corticale à travers différents domaines de la cognition dans une cohorte de 104 personnes âgées cognitivement normales, en tenant compte de l’âge, du sexe et du niveau d’éducation. Tous les participants ont été soumis à une évaluation neuropsychologique détaillée, ainsi qu’à des examens en résonance magnétique (IRM) structurelle et en tomographie par émission de positons (TEP) avec le Pittsburgh Compound B (PIB). La sévérité des HSB a été quantifiée avec l’échelle Age-Related White Matter Changes (ARWMC).
Mis ensemble, les résultats des deux articles empiriques composant cette thèse font ressortir des effets indépendants et additifs de la charge A et du volume de l’hippocampe droit sur la mémoire épisodique, de sorte qu’une pathologie A élevée et un volume plus faible prédisaient des performances moindres. La charge A et les HSB contribuaient de façon additive à une mémoire de travail diminuée et exerçaient des effets délétères synergiques sur la flexibilité mentale et l’attention. Les HSB étaient négativement associés au langage, dont ils étaient le plus important prédicteur. À l’inverse, ni les dépôts A ni les HSB n’étaient corrélés à la mémoire sémantique, la vitesse de traitement de l’information et les fonctions visuospatiales. Dans l’article 1, nous avons démontré que le déclin lié à l’âge au niveau de la mémoire épisodique, la mémoire de travail, la flexibilité mentale et le langage était entièrement médié par le degré de pathologie cérébrale. Dans l’article 2, nous avons démontré qu’il n’y avait pas d’association positive entre les cartes d’épaisseur corticale et les fonctions cognitives, à l’exception de la mémoire sémantique. En outre, la charge A, les HSB et les mesures d’IRM structurelle étaient indépendants les uns des autres, appuyant plutôt la notion de trajectoires physiopathologiques distinctes. Un résultat important de l’article 2 était la relation positive entre la mémoire sémantique et l’épaisseur corticale dans le lobe temporal antérieur (LTA), une région connue pour son rôle unique dans l’intégration des connaissances sémantiques à un niveau transmodal.
Les résultats de cette thèse mettent en lumière le rôle médiateur de pathologies cérébrales prévalentes, soit la charge A et les HSB, dans le vieillissement cognitif, et suggèrent que celles-ci induisent des changements cognitifs par le biais de mécanismes physiopathologiques autres que l’atrophie cérébrale. Sur le plan clinique, nos travaux soulignent la pertinence de diversifier les outils d’évaluation utilisés pour le dépistage des troubles cognitifs chez la personne âgée, avec un accent particulier sur la mémoire sémantique. / Compelling evidence shows that pathological changes are highly prevalent in the aging brain, even in otherwise healthy individuals who remain fully functional. Among the most common age-related brain lesions are the abnormal deposition of beta-amyloid (A) peptide, a well-known hallmark of Alzheimer’s disease (AD), and white matter hyperintensities (WMH), which are regarded as a radiological marker of cerebral small vessel disease. Converging evidence from neuropathological, neuropsychological and neuroimaging data suggests that normal older adults harboring high levels of brain pathology exhibit exacerbated cognitive decline. Thus, neuropathological changes in healthy elderly people deserve particular attention as they are potential targets for early intervention and might contribute to the early identification of AD. This thesis sought to examine the associations between Aβ burden, WMH, cortical thickness and cognitive performances across multiple domains in a cohort of 104 cognitively normal older adults, while accounting for age, sex and years of formal education. All participants underwent an extensive neuropsychological assessment along with structural magnetic resonance imaging (MRI) and positron emission tomography (PET) with Pittsburgh Compound B (PIB). WMH severity was assessed using the age-related white matter changes (ARWMC) scale.
Combined findings from the two empirical articles making up this thesis demonstrate independent, additive effects of A burden and right hippocampal volume on episodic memory whereby increased A deposition and reduced volume predict decreased performance. A burden and WMH contributed additively to poorer working memory and exerted deleterious synergistic effects on mental flexibility and attention. WMH was the most important predictor of linguistic abilities with higher lesion severity being associated with worse performances on language tasks. Conversely, neither A deposition nor WMH were correlated with semantic memory, processing speed and visuospatial abilities. In article 1, we demonstrated that age-dependent decline in episodic memory, working memory, mental flexibility and language was fully mediated by the extent of brain pathology. In article 2, cognition was not found to be positively associated with cortical thickness in the vertex-wise analyses, except for the domain of semantic memory. Furthermore, A burden, WMH and structural MRI measures were independent of one another, supporting the notion of distinct pathophysiological pathways. A notable finding of article 2 was that thinner cortical thickness in the left anterior temporal lobe (ATL) predicted poorer semantic memory, which is coherent with the role of the ATL in heteromodal semantic processing.
The results presented in this thesis shed light on the role of prevalent brain pathologies, namely A burden and WMH, in driving age-related cognitive changes, and suggest that these changes can occur through pathways that are distinct from brain atrophy. Clinically speaking, this work lends support for the inclusion of a wider array of measures to routine screening for cognitive impairment in older adults, with an emphasis on semantic memory.
|
66 |
Magnetic Nanoparticle Hyperthermia-Mediated Clearance of Beta-amyloid Plaques: Implications in the Treatment of Alzheimer’s DiseaseDyne, Eric D. 20 April 2021 (has links)
No description available.
|
67 |
ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture modelMulik, R.S., Monkkonen, J., Juvonen, R.O., Mahadik, K.R., Paradkar, Anant R January 2010 (has links)
No / Beta amyloid plays a main role in the pathophysiology of Alzheimer's disease by inducing oxidative stress in the brain. Curcumin, a natural antioxidant, is known to inhibit beta amyloid and beta amyloid induced oxidative stress. However, low bioavailability and photodegradation are the major concerns for the use of curcumin. In the present study, we have formulated apolipoprotein E3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin (ApoE3-C-PBCA) to provide photostability and enhanced cell uptake of curcumin by targeting. Prepared nanoparticles were characterized for particle size, zeta potential, entrapment efficiency and in vitro drug release. The entrapment of curcumin inside the nanoparticles was confirmed by X-ray diffraction analysis. Physicochemical characterization confirmed the suitability of the method of preparation. The photostability of curcumin was increased significantly in nanoparticles compared to plain curcumin. In vitro cell culture study showed enhanced therapeutic efficacy of ApoE3-C-PBCA against beta amyloid induced cytotoxicity in SH-SY5Y neuroblastoma cells compared to plain curcumin solution. Beta amyloid is known to induce apoptosis in neuronal cells, therefore antiapoptotic activity of curcumin was studied using flow cytometry assays. From all the experiments, it was found that the activity of curcumin was enhanced with ApoE3-C-PBCA compared to plain curcumin solution suggesting enhanced cell uptake and a sustained drug release effect. The synergistic effect of ApoE3 and curcumin was also studied, since ApoE3 also possesses both antioxidant and antiamyloidogenic activity. It was found that ApoE3 did indeed have activity against beta amyloid induced cytotoxicity along with curcumin. Hence, ApoE3-C-PBCA offers great advantage in the treatment of beta amyloid induced cytotoxicity in Alzheimer's disease.
|
68 |
Inhibiting Axon Degeneration in a Mouse Model of Acute Brain Injury Through Deletion of Sarm1Henninger, Nils 24 May 2017 (has links)
Traumatic brain injury (TBI) is a leading cause of disability worldwide. Annually, 150 to 200/1,000,000 people become disabled as a result of brain trauma. Axonal degeneration is a critical, early event following TBI of all severities but whether axon degeneration is a driver of TBI remains unclear. Molecular pathways underlying the pathology of TBI have not been defined and there is no efficacious treatment for TBI.
Despite this significant societal impact, surprisingly little is known about the molecular mechanisms that actively drive axon degeneration in any context and particularly following TBI. Although severe brain injury may cause immediate disruption of axons (primary axotomy), it is now recognized that the most frequent form of traumatic axonal injury (TAI) is mediated by a cascade of events that ultimately result in secondary axonal disconnection (secondary axotomy) within hours to days.
Proposed mechanisms include immediate post-traumatic cytoskeletal destabilization as a direct result of mechanical breakage of microtubules, as well as catastrophic local calcium dysregulation resulting in microtubule depolymerization, impaired axonal transport, unmitigated accumulation of cargoes, local axonal swelling, and finally disconnection. The portion of the axon that is distal to the axotomy site remains initially morphologically intact. However, it undergoes sudden rapid fragmentation along its full distal length ~72 h after the original axotomy, a process termed Wallerian degeneration.
Remarkably, mice mutant for the Wallerian degeneration slow (Wlds) protein exhibit ~tenfold (for 2–3 weeks) suppressed Wallerian degeneration. Yet, pharmacological replication of the Wlds mechanism has proven difficult. Further, no one has studied whether Wlds protects from TAI. Lastly, owing to Wlds presumed gain-of-function and its absence in wild-type animals, direct evidence in support of a putative endogenous axon death signaling pathway is lacking, which is critical to identify original treatment targets and the development of viable therapeutic approaches.
Novel insight into the pathophysiology of Wallerian degeneration was gained by the discovery that mutant Drosophila flies lacking dSarm (sterile a/Armadillo/Toll-Interleukin receptor homology domain protein) cell-autonomously recapitulated the Wlds phenotype. The pro-degenerative function of the dSarm gene (and its mouse homolog Sarm1) is widespread in mammals as shown by in vitro protection of superior cervical ganglion, dorsal root ganglion, and cortical neuron axons, as well as remarkable in-vivo long-term survival (>2 weeks) of transected sciatic mouse Sarm1 null axons. Although the molecular mechanism of function remains to be clarified, its discovery provides direct evidence that Sarm1 is the first endogenous gene required for Wallerian degeneration, driving a highly conserved genetic axon death program.
The central goals of this thesis were to determine (1) whether post-traumatic axonal integrity is preserved in mice lacking Sarm1, and (2) whether loss of Sarm1 is associated with improved functional outcome after TBI. I show that mice lacking the mouse Toll receptor adaptor Sarm1 gene demonstrate multiple improved TBI-associated phenotypes after injury in a closed-head mild TBI model. Sarm1-/- mice developed fewer beta amyloid precursor protein (βAPP) aggregates in axons of the corpus callosum after TBI as compared to Sarm1+/+ mice. Furthermore, mice lacking Sarm1 had reduced plasma concentrations of the phosphorylated axonal neurofilament subunit H, indicating that axonal integrity is maintained after TBI. Strikingly, whereas wild type mice exhibited a number of behavioral deficits after TBI, I observed a strong, early preservation of neurological function in Sarm1-/- animals. Finally, using in vivo proton magnetic resonance spectroscopy, I found tissue signatures consistent with substantially preserved neuronal energy metabolism in Sarm1-/- mice compared to controls immediately following TBI. My results indicate that the Sarm1-mediated prodegenerative pathway promotes pathogenesis in TBI and suggest that anti-Sarm1 therapeutics are a viable approach for preserving neurological function after TBI.
|
Page generated in 0.0331 seconds